Elaine Siegfried, MD – St. Louis University
Treatment options are limited for children with atopic dermatitis (AD). This project was a consensus effort to guide clinical development programs of companies developing new therapies for AD in children. The hope that it will provide a valuable framework for efficient development and approval of desperately-needed new therapies.
This project is complete with a guidance document submitted to the FDA and paper published in Pediatric Dermatology in 2018 (see publications page).